Incidence of hematological toxicities on bispecifics for non-Hodgkin lymphoma published trials
| Reference . | Population . | Drug/target . | N* . | Anemia& . | Neutropenia& . | Thrombocytopenia& . | Febrile neutropenia& . | Lymphopenia& . | Low IgG& . | HLH& . | DIC& . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hutchings et al. (2021)15 | Adult CD20+ NHL | Glofitamab CD20 × CD3 | 35 | NA/0(0%) | NA/9(25.7%) | NA/3(8.3%) | NA/2(5.7%) | NA/NA | NA/NA | NA/NA | NA/NA |
| Dickinson et al. (2022)16 | Adult CD20+ NHL | Glofitamab CD20 × CD3 | 154 | 47(30.5%)/ 10(6.5%) | 58(37.7%)/ 41(26.6%) | 38(24.7%)/12(7.7%) | NA/4(3%) | NA/5(3.2%) | NA/NA | NA/NA | NA/NA |
| Hutchings et al. (2021)17 | Adult CD20+ NHL | Epcoritamab CD20 × CD3 | 68 | 16(23%)/9(13%) | NA/17(25%) | NA/8(12%) | 0/0 | NA/4(6%) | NA/NA | NA/NA | NA/NA |
| Thieblemont et al. (2023)18 | Adult CD20+ NHL | Epcoritamab CD20 × CD3 | 157 | 28(17.8%)/ 16(10.2%) | 34(21.7%)/ 23(14.6%) | 21(13.4%)/9(5.7%) | 4(2.5%)/NA | NA/NA | NA/NA | NA/NA | NA/NA |
| Budde et al. (2022)20 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 197 | 37(18.8%)/ 18(9.1%) | 56(28.4%)/ 50(25%) | 5(2.5%)/4(2%) | 7(3.6%)/ 7(3.6%) | 9(4.5%)/8(4%) | NA/NA | NA/NA | NA/NA |
| Budde et al. (2022)19 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 90 | 12(14%)/7(8%) | 26(28%)/ 24(27%) | 9(10%)/4(4%) | 0/0 | NA/NA | NA/NA | NA/NA | NA/NA |
| Bartlett et al. (2023)21 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 88 | 15(17%)/8(9.1%) | 24(27.3%)/ 19(21.6%) | NA/3(3.4%) | NA/5(5.7%) | NA/NA | NA/NA | NA/NA | NA/NA |
| Bannerji et al. (2022)22 | Adult CD20+ NHL | Odronextamab CD20 × CD3 | 145 | 55(38%)/36(25%) | 35(25%)/ 27(19%) | 40(28%)/20(14%) | NA/NA | 32(22%)/ 28(19%) | NA/NA | NA/NA | NA/NA |
| Reference . | Population . | Drug/target . | N* . | Anemia& . | Neutropenia& . | Thrombocytopenia& . | Febrile neutropenia& . | Lymphopenia& . | Low IgG& . | HLH& . | DIC& . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hutchings et al. (2021)15 | Adult CD20+ NHL | Glofitamab CD20 × CD3 | 35 | NA/0(0%) | NA/9(25.7%) | NA/3(8.3%) | NA/2(5.7%) | NA/NA | NA/NA | NA/NA | NA/NA |
| Dickinson et al. (2022)16 | Adult CD20+ NHL | Glofitamab CD20 × CD3 | 154 | 47(30.5%)/ 10(6.5%) | 58(37.7%)/ 41(26.6%) | 38(24.7%)/12(7.7%) | NA/4(3%) | NA/5(3.2%) | NA/NA | NA/NA | NA/NA |
| Hutchings et al. (2021)17 | Adult CD20+ NHL | Epcoritamab CD20 × CD3 | 68 | 16(23%)/9(13%) | NA/17(25%) | NA/8(12%) | 0/0 | NA/4(6%) | NA/NA | NA/NA | NA/NA |
| Thieblemont et al. (2023)18 | Adult CD20+ NHL | Epcoritamab CD20 × CD3 | 157 | 28(17.8%)/ 16(10.2%) | 34(21.7%)/ 23(14.6%) | 21(13.4%)/9(5.7%) | 4(2.5%)/NA | NA/NA | NA/NA | NA/NA | NA/NA |
| Budde et al. (2022)20 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 197 | 37(18.8%)/ 18(9.1%) | 56(28.4%)/ 50(25%) | 5(2.5%)/4(2%) | 7(3.6%)/ 7(3.6%) | 9(4.5%)/8(4%) | NA/NA | NA/NA | NA/NA |
| Budde et al. (2022)19 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 90 | 12(14%)/7(8%) | 26(28%)/ 24(27%) | 9(10%)/4(4%) | 0/0 | NA/NA | NA/NA | NA/NA | NA/NA |
| Bartlett et al. (2023)21 | Adult CD20+ NHL | Mosunetuzumab CD20 × CD3 | 88 | 15(17%)/8(9.1%) | 24(27.3%)/ 19(21.6%) | NA/3(3.4%) | NA/5(5.7%) | NA/NA | NA/NA | NA/NA | NA/NA |
| Bannerji et al. (2022)22 | Adult CD20+ NHL | Odronextamab CD20 × CD3 | 145 | 55(38%)/36(25%) | 35(25%)/ 27(19%) | 40(28%)/20(14%) | NA/NA | 32(22%)/ 28(19%) | NA/NA | NA/NA | NA/NA |